Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms.

BACKGROUND Hepatitis C virus (HCV) infection is prevalent in patients undergoing hemodialysis and is associated with greater mortality. We determined the efficacy and harms of interferon (IFN) and pegylated IFN (PEG-IFN) treatment of hemodialysis patients with chronic HCV infection and identified factors associated with these outcomes. STUDY DESIGN Meta-analysis and meta-regression of randomized controlled trials, uncontrolled trials, and prospective observational studies. SETTING & POPULATION Hemodialysis patients with chronic HCV infection. SELECTION CRITERIA FOR STUDIES MEDLINE indexed studies since 1966, sample size greater than 10. INTERVENTION IFN-based treatment, including PEG-IFN with and without ribavirin. OUTCOMES Sustained virological response (SVR) 6 months after treatment, rate of treatment discontinuation caused by adverse events, and factors associated with these outcomes. RESULTS 20 studies of 459 IFN-treated patients, 3 studies of 38 PEG-IFN-treated patients, and 2 studies of 49 PEG-IFN and ribavirin-treated patients met inclusion criteria. The overall SVR rate was 41% (95% confidence interval [CI], 33 to 49) for IFN and 37% (95% CI, 9 to 77) for PEG-IFN. Treatment discontinuation rates were 26% (95% CI, 20 to 34) for IFN and 28% (95% CI, 12 to 53) for PEG-IFN. SVR was higher with 3 million units (MU) or higher of IFN 3 times weekly, with lower mean HCV RNA, and with lower rates of cirrhosis, HCV genotype 1 or elevated transaminase, but these findings were not statistically significant. Treatment discontinuation rates were greater in studies using larger doses. LIMITATIONS Publication bias, few randomized controlled trials, and limitations in generalizability to all hemodialysis patients. CONCLUSION IFN treatment of hemodialysis patients results in an SVR rate of 41%. Higher dose, lower mean HCV RNA level, and lower rates of cirrhosis, transaminase level increase, and HCV genotype 1 may be associated with greater SVR rates, but additional studies using individual patient data are needed.

[1]  F. Schena,et al.  The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. , 2007, Journal of hepatology.

[2]  S. Greenland,et al.  Hepatitis C virus and death risk in hemodialysis patients. , 2006, Journal of the American Society of Nephrology : JASN.

[3]  I. Sporea,et al.  Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. , 2006, World journal of gastroenterology.

[4]  Mahdia A Buargub,et al.  Tolerance and efficacy of interferon-alpha in hemodialysis patients in Tripoli. , 2006, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[5]  J. Pestana,et al.  Efficacy and tolerance of interferon‐α in the treatment of chronic Hepatitis C in end‐stage renal disease patients on hemodialysis , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[6]  S. Hoşoğlu,et al.  Efficacy and tolerability of pegylated‐interferon alpha‐2a in hemodialysis patients with chronic hepatitis C , 2006, Journal of gastroenterology and hepatology.

[7]  M. Russo,et al.  Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  Christopher H Schmid,et al.  In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. , 2005, Journal of clinical epidemiology.

[9]  F. Fabrizi,et al.  Hepatitis C Virus Antibody Status and Survival After Renal Transplantation: Meta‐Analysis of Observational Studies , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  O. Dalgard.  Follow-up studies of treatment for hepatitis C virus infection among injection drug users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  C. Datz,et al.  High-dose interferon-α2b treatment prevents chronicity in acute hepatitis C , 1996, Digestive Diseases and Sciences.

[12]  F. Fabrizi,et al.  Meta‐analysis: effect of hepatitis C virus infection on mortality in dialysis , 2004, Alimentary pharmacology & therapeutics.

[13]  A. Al-Khader,et al.  Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. , 2004, Transplantation proceedings.

[14]  Z. Mareček,et al.  Treatment of Early Diagnosed HCV Infection in Hemodialyzed Patients with Interferon-α. Treatment of Hepatitis C , 2004, Blood Purification.

[15]  M. Haberal,et al.  A Six‐Year Follow‐Up After Interferon‐Alpha Monotherapy for Chronic Hepatitis C Infection in Hemodialysis Patients , 2004, Renal failure.

[16]  M. Jadoul,et al.  Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. , 2003, Kidney international.

[17]  F. Fabrizi,et al.  Meta‐analysis: interferon for the treatment of chronic hepatitis C in dialysis patients , 2003, Alimentary pharmacology & therapeutics.

[18]  Tadashi Takeda,et al.  Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: A population‐based cohort study , 2003, Journal of medical virology.

[19]  L. Rostaing,et al.  Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. , 2003, Journal of the American Society of Nephrology : JASN.

[20]  M. Sherman,et al.  Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. , 2003, Journal of hepatology.

[21]  M. Russo,et al.  Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety , 2003, American Journal of Gastroenterology.

[22]  J. Pawlotsky.  Use and interpretation of virological tests for hepatitis C , 2002, Hepatology.

[23]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[24]  M. Sata,et al.  Interferon therapy prolonged life expectancy among chronic hepatitis C patients. , 2002, Gastroenterology.

[25]  R. Sentjens,et al.  Performance of the New Bayer VERSANT HCV RNA 3.0 Assay for Quantitation of Hepatitis C Virus RNA in Plasma and Serum: Conversion to International Units and Comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, Assay , 2002, Journal of Clinical Microbiology.

[26]  E. Konnick,et al.  Performance Characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit Assay and the National Genetics Institute HCV Superquant Assay , 2002, Journal of Clinical Microbiology.

[27]  S. Huraib,et al.  Sustained Virological and Histological Response with Pretransplant Interferon Therapy in Renal Transplant Patients with Chronic Viral Hepatitis C , 2001, American Journal of Nephrology.

[28]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[29]  C. Schmid,et al.  Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease , 2001, Annals of Internal Medicine.

[30]  O. Toupance,et al.  Virological and Histological Responses to One Year Alpha-Interferon-2a in Hemodialyzed Patients with Chronic Hepatitis C , 2001, Nephron.

[31]  A. Morabito,et al.  Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. , 2001, Journal of hepatology.

[32]  S. Chevret,et al.  The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  T. Serrano,et al.  Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. , 2001 .

[34]  M. L. de la Mata,et al.  Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. , 2001, Clinical nephrology.

[35]  N. Ozdemir,et al.  Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. , 2001 .

[36]  T. Berg,et al.  Randomized, double‐blind, placebo‐controlled trial of interferon Alfa2a with and without amantadine as initial treatment for chronic hepatitis C , 2000, Hepatology.

[37]  J. Campistol,et al.  Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[38]  Yasuyuki Arakawa,et al.  Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.

[39]  A. Abdulla,et al.  Interferon-α in chronic hepatitis C infection in dialysis patients , 1999 .

[40]  O. Weiland,et al.  Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. , 1999, Journal of hepatology.

[41]  L. Rostaing,et al.  Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. , 1998, Journal of the American Society of Nephrology : JASN.

[42]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[43]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[44]  B. Kasiske.  Meta-analysis as a clinical tool in nephrology. , 1998, Kidney international.

[45]  M. Caremani,et al.  Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C. , 1998, Current medical research and opinion.

[46]  L. Rostaing,et al.  High Rate of Hepatitis C Virus Clearance in Hemodialysis Patients after Interferon-α Therapy , 1997 .

[47]  P. Marcellin,et al.  Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon- Therapy , 1997, Annals of Internal Medicine.

[48]  A. Lok,et al.  Interferon treatment for hepatitis C virus infection in patients on haemodialysis. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[49]  P. Rendo,et al.  A double‐blind controlled trial of recombinant interferon‐α2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels , 1997 .

[50]  M. Raptopoulou-Gigi,et al.  Interferon-α2b treatment of chronic hepatitis C in haemodialysis patients , 1995 .

[51]  H. Hayashi,et al.  Interferon treatment for chronic hepatitis C in haemodialysis patients: Suggestions based on a small series , 1995, Journal of gastroenterology and hepatology.

[52]  F. Carnot,et al.  Efficacy and tolerance of α-2b interferon therapy on HCV infection of hemodialyzed patients , 1995 .

[53]  A. Aldrees,et al.  High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saudi Arabia: a need for new dialysis strategies. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[54]  W. Vogel,et al.  Interferon treatment for chronic hepatitis C virus infection in uremic patients. , 1994, Kidney international.

[55]  K. Dickersin,et al.  Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. , 1992, JAMA.